Literature DB >> 26907706

Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense.

Yuanyuan Kong1, Hong You2, Jidong Jia3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26907706     DOI： 10.1007/s12072-016-9714-9

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  22 in total

1.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

3.  Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.

Authors:  G V Papatheodoridis; S Manolakopoulos; G Touloumi; G Nikolopoulou; M Raptopoulou-Gigi; C Gogos; I Vafiadis-Zouboulis; D Karamanolis; A Chouta; A Ilias; C Drakoulis; K Mimidis; I Ketikoglou; E Manesis; M Mela; G Hatzis; G N Dalekos
Journal:  J Viral Hepat       Date:  2014-07-15       Impact factor: 3.728

4.  Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.

Authors:  Gi-Ae Kim; Han Chu Lee; Min-Ju Kim; Yeonjung Ha; Eui Ju Park; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim
Journal:  J Hepatol       Date:  2014-11-28       Impact factor: 25.083

Review 5.  Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

Authors:  Uchenna H Iloeje; Hwai-I Yang; Chien-Jen Chen
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

6.  Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.

Authors:  Takao Watanabe; Yoshio Tokumoto; Kouji Joko; Kojiro Michitaka; Toshie Mashiba; Atsushi Hiraoka; Hironori Ochi; Yohei Koizumi; Fujimasa Tada; Masashi Hirooka; Osamu Yoshida; Yusuke Imai; Masanori Abe; Yoichi Hiasa
Journal:  Hepatol Int       Date:  2015-07-22       Impact factor: 6.047

Review 7.  Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

Authors:  Alessio Aghemo; Pietro Lampertico; Massimo Colombo
Journal:  J Hepatol       Date:  2012-06-28       Impact factor: 25.083

8.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Christy Wing-Hin Mak; Stanley King-Yeung Lee; Zoe Man-Yi Ip; Andrew Ting-Ho Lam; Henry Wing-Hang Iu; Joyce May-Sum Leung; Jennifer Wing-Yan Lai; Angeline Oi-Shan Lo; Hoi-Yun Chan; Vincent Wai-Sun Wong
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

Review 9.  Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.

Authors:  Il Han Song; So Mi Kim; Young Kwang Choo
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

10.  Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.

Authors:  Pauline Arends; Milan J Sonneveld; Roeland Zoutendijk; Ivana Carey; Ashley Brown; Massimo Fasano; David Mutimer; Katja Deterding; Jurriën G P Reijnders; Ye Oo; Jörg Petersen; Florian van Bömmel; Robert J de Knegt; Teresa Santantonio; Thomas Berg; Tania M Welzel; Heiner Wedemeyer; Maria Buti; Pierre Pradat; Fabien Zoulim; Bettina Hansen; Harry L A Janssen
Journal:  Gut       Date:  2014-07-10       Impact factor: 23.059
View more
  1 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.